HRMY — Harmony Biosciences Holdings, Inc. stock price, charts and financials

QT63Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
35.60
+0.36+1.02%
OverviewShort InterestFilings
HRMYQT63Harmony Biosciences Holdings, Inc.·NASDAQ
35.60+1.02%
TA
Loading chart...
Screen all →
BHVN-0.96%$13.37ZLAB-0.49%$18.18PVLA+1.25%$140.78ZBIO-0.99%$31.13NBTX+1.32%$38.89ADMA+3.31%$8.74RAPP-0.46%$40.79SION+4.52%$49.26
Snapshot
Index-P/E13.98EPS (ttm)2.52Insider Own-Shs Outstand57.89MPerf Week-0.23%
Market Cap2.04BForward P/E8.46EPS next Y4.16Insider Trans0.00%Shs Float50.37MPerf Month-2.11%
Enterprise Value1.66BPEG-EPS next Q-Inst Own-Short Float10.15%Perf Quarter12.73%
Income145.87MP/S2.27EPS this Y40.07%Inst Trans-Short Ratio6.01Perf Half Y-4.40%
Sales899.12MP/B2.24EPS next Y19.89%ROA11.45%Short Interest5.11MPerf YTD-5.83%
Book/sh-P/C5.96EPS next 5Y13.17%ROE17.19%52W High41.29 -13.78%Perf Year-0.68%
Cash/sh-P/FCF5.97EPS past 3/5Y-3.01% -ROIC12.50%52W Low25.78 38.09%Perf 3Y-0.73%
Dividend Est.-EV/EBITDA7.10Sales past 3/5Y25.61% 40.24%Gross Margin76.55%Volatility3.20% 4.03%Perf 5Y19.74%
Dividend TTM-EV/Sales1.84EPS Y/Y TTM-1.20%Oper. Margin21.08%ATR (14)1.37Perf 10Y-
Dividend Ex-Date-Quick Ratio3.56Sales Y/Y TTM25.59%Profit Margin16.20%RSI (14)50.02Recom2.54
Dividend Gr. 3/5Y-Current Ratio3.58EPS Q/Q-29.49%SMA20-1.57%Beta0.94Target Price44.00
Payout0.00%Debt/Eq0.23Sales Q/Q16.22%SMA502.72%Rel Volume0.73Prev Close35.24
Employees293LT Debt/Eq0.18EarningsAug 04SMA2006.65%Avg Volume823.71KPrice35.60
IPO DateAug 19, 2020Option/ShortYes / YesEPS/Sales Surpr.-20.83% -2.47%Net Debt/EBITDA-1.64Volume604,885Change1.02%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-30-26ReiteratedDeutsche BankHold$31 → $36
Feb-23-26ReiteratedDeutsche BankBuy$31
Feb-19-26ReiteratedMizuho SecuritiesOutperform$46 → $50
Feb-11-26DowngradeUBSBuy → Neutral$43 → $46
Jan-08-26ReiteratedTruist SecuritiesBuy$45
Dec-01-25ReiteratedMizuhoOutperform$36 → $46
Nov-24-25ReiteratedOppenheimerOutperform$56 → $62
Oct-29-25ReiteratedMizuho SecuritiesOutperform$35 → $36
Oct-15-25ReiteratedUBSBuy$48 → $43
Sep-25-25ReiteratedHC Wainwright & Co.Buy$55
Latest News
Jul-31-26
Jul-31-2601:01PM
4 Value Stocks to Buy as Fed Holds Rates, Mideast Risks Risezacks.com
Jul-30-26
Jul-30-2612:41PM
HRMY or ACAD: Which Is the Better Value Stock Right Now?zacks.com
10:41AM
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?zacks.com
Jul-28-26
Jul-28-2612:41PM
5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfoliozacks.com
12:00PM
Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruptionseekingalpha.com
11:06AM
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growthzacks.com
Jul-27-26
Jul-27-2601:41PM
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?zacks.com
Jul-22-26
Jul-22-2609:01AM
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?zacks.com
Jul-21-26
Jul-21-2608:05AM
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026globenewswire.com
Jul-17-26
Jul-17-2603:26PM
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transitionzacks.com
Jul-16-26
Jul-16-2612:24PM
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price TargetBenzinga
08:30AM
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transitionbusinesswire.com
Jul-15-26
Jul-15-2610:55AM
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?zacks.com
Jul-14-26
Jul-14-2612:40PM
HRMY vs. AMGN: Which Stock Is the Better Value Option?zacks.com
11:31AM
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returnszacks.com
Company

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue89886871558243830516060
Cost of Goods Sold Incl. D&A21219815712183562820
Gross Profit68867055846135425013240
Selling, General and Administrative Excl. Other274272221193163132968129
Research and Development224190146767130197012
Other Operating Expense1000000-10
Operating Income1892081911921208817-146-41
Interest Expense1515172419242860
Unusual Expense
—————————
Non-Operating Income (Expense)23211853-26-2602
Net Income Before Taxes19821519217310537-37-152-40
Income Taxes52564645-773000
Consolidated Net Income14515914512918135-37-152-40
Net Income From Continuing Operations14515914512918135-37-152-40
Net Income14515914512918135-37-152-40
EPS (Recurring)2.522.762.562.173.070.60-1.12-2.94-1.42
EPS (Basic, Before Extraordinaries)2.522.762.562.173.070.60-1.12-2.94-1.42
EPS (Diluted)2.482.712.512.132.970.58-1.10-2.94-1.42
EBITDA233255233222147802-143-41
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio14.3513.8113.7115.1618.5573.52———
Price To Sales Ratio2.302.462.743.277.428.1112.88——
Gross Margin76.6177.1978.0479.2180.8281.9782.5066.67—
Operating Margin21.0523.9626.7132.9927.4028.8510.63-2,433.33—
Net Margin16.1518.3220.2822.1641.3211.48-23.13-2,533.33—
Shares Outstanding585757595958576449
Market Capitalization2,0652,1331,9611,9063,2512,4732,061——
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$42.70$37.95$33.20$28.46$23.71● Close Price0.00M0.26M0.51M0.77M1.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Budur KumarCHIEF MEDICAL OFFICERMay 01 '26Option Exercise0.0018,750032,997May 18
Zaeske Adam H.CHIEF COMMERCIAL OFFICERApr 07 '26Option Exercise0.007,50007,500Apr 09
Kapadia SandipCHIEF FINANCIAL OFFICERJan 26 '26Sale37.153,746139,17124,521Jan 28
Dayno Jeffrey M.PRESIDENT, CEOJan 25 '26Option Exercise0.0013,000013,000Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 25 '26Option Exercise0.004,72504,725Jan 26
Serafin AndrewCHIEF STRATEGY OFFICERJan 25 '26Option Exercise0.002,60002,600Jan 26
Budur KumarCHIEF MEDICAL OFFICERJan 25 '26Option Exercise0.002,66202,662Jan 26
Serafin AndrewCHIEF STRATEGY OFFICERJan 24 '26Option Exercise0.002,50002,500Jan 26
Budur KumarCHIEF MEDICAL OFFICERJan 24 '26Option Exercise0.002,18802,188Jan 26
Dayno Jeffrey M.PRESIDENT, CEOJan 24 '26Option Exercise0.0010,500010,500Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 24 '26Option Exercise0.003,81303,813Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 15 '26Sale35.9220,961752,8330Jan 20
Dayno Jeffrey M.PRESIDENT, CEODec 12 '25Sale40.115,933237,9570Dec 17
Dayno Jeffrey M.PRESIDENT, CEODec 12 '25Option Exercise8.2220,000164,40020,000Dec 17
Kapadia SandipCHIEF FINANCIAL OFFICERDec 05 '25Option Exercise29.0320,000580,60020,000Dec 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.